Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alpha Tau Medical Ltd DRTS

Healthcare Medical Devices
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor... see more

Recent & Breaking News (NDAQ:DRTS)

Alpha Tau to Present at Upcoming November Investor Conferences

GlobeNewswire November 9, 2022

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

GlobeNewswire October 21, 2022

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy

GlobeNewswire September 8, 2022

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

GlobeNewswire September 1, 2022

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

GlobeNewswire August 30, 2022

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 25, 2022

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

GlobeNewswire August 22, 2022

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

GlobeNewswire July 5, 2022

Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT(TM)

PR Newswire June 22, 2022

Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site

PR Newswire June 16, 2022

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT(TM) in Recurrent Cutaneous SCC

PR Newswire June 8, 2022

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors

PR Newswire June 7, 2022

Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 26, 2022

First Alpha DaRT Patients Treated in France as Part of Alpha DaRT(TM) Multicenter Skin Cancer Trial

PR Newswire May 23, 2022

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update

PR Newswire March 28, 2022

Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination

PR Newswire March 7, 2022

Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer

PR Newswire January 20, 2022

Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer

PR Newswire January 3, 2022